Dahan-Farkas et al., 2011 - Google Patents
6-Substituted imidazo [1, 2-a] pyridines: Synthesis and biological activity against colon cancer cell lines HT-29 and Caco-2Dahan-Farkas et al., 2011
View PDF- Document ID
- 13791938630910806813
- Author
- Dahan-Farkas N
- Langley C
- Rousseau A
- Yadav D
- Davids H
- de Koning C
- Publication year
- Publication venue
- European journal of medicinal chemistry
External Links
Snippet
A range of 6-substituted imidazo [1, 2-a] pyridines were synthesized using a multicomponent coupling reaction. Most of these compounds were found to exhibit excellent activity against the colon cancer cell lines HT-29 and Caco-2, whilst not showing significant toxicity against …
- 230000000694 effects 0 title abstract description 39
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulfur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dahan-Farkas et al. | 6-Substituted imidazo [1, 2-a] pyridines: Synthesis and biological activity against colon cancer cell lines HT-29 and Caco-2 | |
Abdelhafez et al. | Synthesis, anticoagulant and PIVKA-II induced by new 4-hydroxycoumarin derivatives | |
EP2922828B1 (en) | 4,6-diamino-pyrimidine derivatives as bmi-1 inhibitors for treating cancer | |
Kilic-Kurt et al. | Synthesis and anticancer activity of some pyrimidine derivatives with aryl urea moieties as apoptosis-inducing agents | |
AU2018271277A1 (en) | Substituted pyrimidine Bmi-1 inhibitors | |
CA2692922C (en) | Azaindole-indole coupled derivatives, preparation methods and uses thereof | |
EP2190836A1 (en) | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors | |
Hajri et al. | Synthesis and evaluation of in vitro antiproliferative activity of new ethyl 3-(arylethynyl) quinoxaline-2-carboxylate and pyrido [4, 3-b] quinoxalin-1 (2H)-one derivatives | |
Zhang et al. | Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1, 3, 5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors | |
JP7166252B2 (en) | 3-amino-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-ones as cyclin-dependent kinase inhibitors | |
Ling et al. | Development of novel amino-quinoline-5, 8-dione derivatives as NAD (P) H: quinone oxidoreductase 1 (NQO1) inhibitors with potent antiproliferative activities | |
Wang et al. | Synthesis and bioevaluation and doking study of 1H-pyrrolo [2, 3-b] pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors | |
Zhang et al. | Multicomponent assembly of novel antiproliferative steroidal dihydropyridinyl spirooxindoles | |
Pati et al. | Novel metal chelators thiosemicarbazones with activity at the σ 2 receptors and P-glycoprotein: an innovative strategy for resistant tumor treatment | |
Duan et al. | Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1, 4-benzodioxan moiety as FAK inhibitors with anticancer activity | |
Li et al. | Design, synthesis and biological evaluation of N-phenyl-(2, 4-dihydroxypyrimidine-5-sulfonamido) benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs | |
Liu et al. | DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions | |
EP2417136A1 (en) | Imidaz0ý1,2-a¨pyridine-6-carboxamide derivatives, their use for the treatment of colon cancer and their method of manufacture | |
EP2397471A1 (en) | Benzimidazole compounds and their use | |
AU2016238523A1 (en) | Fused bicyclic compounds for the treatment of disease | |
Badithapuram et al. | Design, synthesis, and molecular docking studies of some new quinoxaline derivatives as EGFR targeting agents | |
El-Hussieny et al. | Synthesis, biological evaluation and molecular docking of new sulfonamide-based indolinone derivatives as multitargeted kinase inhibitors against leukemia | |
Bortolozzi et al. | Targeting tubulin polymerization by novel 7-aryl-pyrroloquinolinones: Synthesis, biological activity and SARs | |
Huang et al. | Design, synthesis and anticancer activity of novel 6-(aminophenyl)-2, 4-bismorpholino-1, 3, 5-triazine derivatives bearing arylmethylene hydrazine moiety | |
Belskaya et al. | The new facile and straightforward method for the synthesis of 4H-1, 2, 3-thiadiazolo [5, 4-b] indoles and determination of their antiproliferative activity |